| Description |
Inbakicept (ALT-803) is an IL-15 superagonist complex, consisting of IL-15 mutant and IL-15Rα-Fc fusion. Inbakicept magnifies anti-CD20 mAb-mediated NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation, IFNγ production in cells[1].
|
| Related Catalog |
|
| Target |
IL-15Rα
|
| In Vitro |
Inbakicept (0.01-1 nM；20 小时) 增强人 NK 细胞的细胞毒性并增加细胞毒性效应分子的表达[1]。 Cell Cytotoxicity Assay[1] Cell Line: Daudi, Raji, CD19+ FL cells Concentration: 0.01 nM, 0.1 nM, and 1 nM Incubation Time: 20 hours Result: Increased the human NK cell cytotoxicity on Daudi, Raji, CD19+ FL cells.
|
| In Vivo |
Inbakicept (0.2 mg/kg；静脉注射；每周两次，持续 2 周) 在小鼠模型中增强利妥昔单抗对致死性 Daudi 淋巴瘤攻击的保护作用[1]。 Animal Model: SCID mice with Daudi models[1] Dosage: 0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg Administration: Intravenous injection; twice weekly, for 2 weeks Result: Enhanced rituximab-directed control of Raji lymphoma challenge.
|
| References |
[1]. Rosario M, et al. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016 Feb 1;22(3):596-608.
|
